BR112018067312A2 - compostos e composições farmacêuticas dos mes-mos para o tratamento da fibrose - Google Patents

compostos e composições farmacêuticas dos mes-mos para o tratamento da fibrose

Info

Publication number
BR112018067312A2
BR112018067312A2 BR112018067312A BR112018067312A BR112018067312A2 BR 112018067312 A2 BR112018067312 A2 BR 112018067312A2 BR 112018067312 A BR112018067312 A BR 112018067312A BR 112018067312 A BR112018067312 A BR 112018067312A BR 112018067312 A2 BR112018067312 A2 BR 112018067312A2
Authority
BR
Brazil
Prior art keywords
diseases
treatment
compositions
fibrosis
pharmaceutical compounds
Prior art date
Application number
BR112018067312A
Other languages
English (en)
Inventor
Marie Elise Palisse Adeline
Allart Brigitte
Martine Andrée Marie Joannesse Caroline
Jeanne Marie Menet Christel
Karel Jansen Koen
Mammoliti Oscar
El Bkassiny Sandy
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of BR112018067312A2 publication Critical patent/BR112018067312A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

a presente invenção descreve os compostos de acordo com a fórmula i: ia em que r1a, r1b, r2a, r2b, r3, r4, r5, r6a, x, cy1, cy2, e a subscrição n e m são como definidos aqui. a presente invenção refere-se a compostos antagonistas do receptor de esfingosina 1-fosfato (s1p), métodos para sua produção, composições farmacêuticas compreendendo os mesmos, e métodos de tratamento usado os mesmos, para a profilaxia e/ou tratamento de doenças envolvendo doenças fibróticas, doenças inflamatórias, doenças autoimunes, doenças metabólicas, doenças cardiovasculares, e/ou doenças proliferativas administrando-se o composto da invenção.
BR112018067312A 2016-03-04 2017-02-23 compostos e composições farmacêuticas dos mes-mos para o tratamento da fibrose BR112018067312A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1603745.9A GB201603745D0 (en) 2016-03-04 2016-03-04 Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
PCT/EP2017/054139 WO2017148787A1 (en) 2016-03-04 2017-02-23 Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis

Publications (1)

Publication Number Publication Date
BR112018067312A2 true BR112018067312A2 (pt) 2018-12-26

Family

ID=55858990

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018067312A BR112018067312A2 (pt) 2016-03-04 2017-02-23 compostos e composições farmacêuticas dos mes-mos para o tratamento da fibrose

Country Status (19)

Country Link
US (1) US20190388421A1 (pt)
EP (1) EP3423445B1 (pt)
JP (1) JP2019507766A (pt)
KR (1) KR20180118752A (pt)
CN (1) CN108699037A (pt)
AR (1) AR107798A1 (pt)
AU (1) AU2017227900A1 (pt)
BR (1) BR112018067312A2 (pt)
CA (1) CA3016185A1 (pt)
CO (1) CO2018009876A2 (pt)
GB (1) GB201603745D0 (pt)
IL (1) IL261444A (pt)
MX (1) MX2018010218A (pt)
PH (1) PH12018501849A1 (pt)
RU (1) RU2018134780A (pt)
SG (1) SG11201807540UA (pt)
TW (1) TW201734005A (pt)
WO (1) WO2017148787A1 (pt)
ZA (1) ZA201805601B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019091999A1 (en) 2017-11-08 2019-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) S1pr2 antagonists for treating diseases involving abnormal immune responses
MA50905A (fr) 2017-11-15 2020-09-23 Galapagos Nv Composés et compositions pharmaceutiques de ceux-ci destinés à être utilisés dans le traitement de maladies fibrotiques
BR112020015620A2 (pt) * 2018-02-02 2021-01-05 Qingdao Kingagroot Chemical Compound Co., Ltd. Composto de piridazinol com anel de cinco membros substituído e seus derivados, método de preparação, composição herbicida, e aplicação
CN110878086B (zh) * 2018-09-06 2024-06-07 青岛清原化合物有限公司 五元环取代的哒嗪醇类化合物及其衍生物、制备方法、除草组合物和应用
CN109053693B (zh) * 2018-09-20 2021-02-05 顺毅股份有限公司 哒嗪胺类化合物的制备及其应用
CN110128457B (zh) * 2019-05-24 2022-05-03 宁波瑞奇医药科技有限公司 杂环小分子化合物的制备方法
US11485727B2 (en) * 2019-07-22 2022-11-01 Boehringer Ingelheim International Gmbh N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxin (ATX) modulators
US11465982B2 (en) * 2019-07-22 2022-10-11 Boehringer Ingelheim International Gmbh Pyridazines
CN111777549A (zh) * 2020-07-07 2020-10-16 中瀚(齐河县)生物医药科技有限公司 一种2-甲氧基-3-溴-5-氟吡啶的合成工艺
WO2023069721A2 (en) * 2021-10-22 2023-04-27 Carmot Therapeutics, Inc. Oxazole, oxadiazole, and indole derivatives for the inhibition of usp28

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1156803A4 (en) * 1999-02-09 2004-03-17 Bristol Myers Squibb Co FXA LACTAM INHIBITORS AND METHOD
CN101918360A (zh) * 2007-09-24 2010-12-15 阿勒根公司 具有1-磷酸-鞘氨醇(s1p)受体生物学活性的带芳基或者杂芳基基团的吲哚化合物

Also Published As

Publication number Publication date
CO2018009876A2 (es) 2018-10-10
SG11201807540UA (en) 2018-09-27
PH12018501849A1 (en) 2019-01-28
CN108699037A (zh) 2018-10-23
KR20180118752A (ko) 2018-10-31
MX2018010218A (es) 2018-11-09
AR107798A1 (es) 2018-06-06
US20190388421A1 (en) 2019-12-26
WO2017148787A1 (en) 2017-09-08
EP3423445A1 (en) 2019-01-09
ZA201805601B (en) 2019-06-26
RU2018134780A (ru) 2020-04-06
GB201603745D0 (en) 2016-04-20
EP3423445B1 (en) 2020-04-01
CA3016185A1 (en) 2017-09-08
IL261444A (en) 2018-10-31
AU2017227900A1 (en) 2018-10-25
TW201734005A (zh) 2017-10-01
JP2019507766A (ja) 2019-03-22

Similar Documents

Publication Publication Date Title
BR112018067312A2 (pt) compostos e composições farmacêuticas dos mes-mos para o tratamento da fibrose
AR124916A2 (es) Piridinas sustituidas con heteroarilo y métodos de uso
CO2020000056A2 (es) Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de la fibrosis
BR112018070602A2 (pt) composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
BR112015020998A2 (pt) compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios
PH12016502081A1 (en) Compounds for treating spinal muscular atrophy
BR112016025048A2 (pt) compostos e composições como agonistas do receptor tipo toll7
MX2018005890A (es) Composiciones para tratar atrofia muscular espinal.
BR112017022008A2 (pt) composições de di-hidropiridoisoquinolinonas e composições farmacêuticas das mesmas para o tratamento de transtornos inflamatórios
EA201692176A1 (ru) Полифторзамещенное соединение в качестве ингибитора тирозинкиназы брутона (btk)
PH12017500416A1 (en) Compounds and compositions as raf kinase inhibitors
EA201791941A1 (ru) Бициклические кетосульфонамидные соединения
BR112017026132A2 (pt) piridinas substituídas e métodos de uso
BR112017023740A2 (pt) ?forma sólida de um composto, processo para a preparação de uma forma sólida, composição farmacêutica, método para o tratamento ou prevenção de doenças e utilização de uma forma sólida?
PH12018501434A1 (en) Cyclic amine derivative and medical use thereof
BR112017004173A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou condição patológica.
BR112018006866A2 (pt) compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos
BR112021019055A2 (pt) Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios
EA201700042A1 (ru) Соединения имидазопиридазина
BR112021019099A2 (pt) Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
MX2015008733A (es) Derivados de 1,2,3-triazol-4-amina para el tratamiento de enfermedades y transtornos relacionados con receptores sigma.
EA201892098A1 (ru) Соединение, обладающее ингибирующей мутантную idh активностью, способ его получения и применения
MX2018007517A (es) Compuestos triciclicos y composiciones como inhibidores de quinasa.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]